Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459372 | 0.94 | ALDH1A1 (0.43) | THRBLMNAPOLBALDH1A1KDM4E | |
| SCHEMBL5452963 | 0.89 | ALDH1A1 (0.41) | THRBLMNAPOLBALDH1A1KDM4E | |
| SCHEMBL5353717 | 0.87 | KDM4E (0.43) | LMNAPOLBALDH1A1KDM4EHPGD | |
| SCHEMBL5354114 | 0.87 | KDM4E (0.42) | LMNAPOLBALDH1A1KDM4EHPGD | |
| SCHEMBL5474076 | 0.85 | KDM4E (0.42) | LMNAPOLBALDH1A1KDM4EHPGD | |
| SCHEMBL5346954 | 0.81 | ALDH1A1 (0.50) | THRBLMNAPOLBALDH1A1KDM4E | |
| SCHEMBL5464589 | 0.81 | ALDH1A1 (0.45) | THRBLMNATP53ALDH1A1KDM4E | |
| SCHEMBL5361936 | 0.80 | ALDH1A1 (0.45) | THRBLMNATP53POLBALDH1A1 | |
| SCHEMBL5372559 | 0.79 | ALDH1A1 (0.46) | THRBLMNATP53ALDH1A1KDM4E | |
| SCHEMBL5351360 | 0.79 | ALDH1A1 (0.42) | THRBLMNAPOLBALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2007130499-A2 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | THRB 4510/4885LMNA 4460/4885TP53 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.